Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare change-of-heart over ICD data

This article was originally published in The Gray Sheet

Executive Summary

CMS will not seek access to interim data from NIH's Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), despite earlier plans to meet with agency to determine why the study's data safety monitoring board opted to allow patients to continue in the placebo arm (1"The Gray Sheet" March 31, 2003, p. 3). According to the Centers for Medicare & Medicaid Services, access to the interim data would jeopardize the blinded nature of the study and ultimately would be less relevant than the trial's complete results, expected by 2004. CMS instead will try to achieve detailed knowledge of SCD-HeFT patient characteristics and learn from NIH which factors led the DSMB to make its decision...

You may also be interested in...

Tunis Presses NIH To Share ICD Study Findings; Dollens Claims Data Irrelevant

CMS will contact the National Heart, Lung & Blood Institute within the next two weeks to try to determine why SCD-HeFT study patients who met the MADIT-II trial criteria were not switched to the active ICD treatment arm

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts